Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.

MLA

Gravina, Giovanni Luca, et al. “Dual PI3K/MTOR Inhibitor, XL765 (SAR245409), Shows Superior Effects to Sole PI3K [XL147 (SAR245408)] or MTOR [Rapamycin] Inhibition in Prostate Cancer Cell Models.” Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine, vol. 37, no. 1, Jan. 2016, pp. 341–51. EBSCOhost, https://doi.org/10.1007/s13277-015-3725-3.

APA

Gravina, G. L., Mancini, A., Scarsella, L., Colapietro, A., Jitariuc, A., Vitale, F., Marampon, F., Ricevuto, E., & Festuccia, C. (2016). Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine, 37(1), 341–351. https://doi.org/10.1007/s13277-015-3725-3

Chicago

Gravina, Giovanni Luca, Andrea Mancini, Luca Scarsella, Alessandro Colapietro, Ana Jitariuc, Flora Vitale, Francesco Marampon, Enrico Ricevuto, and Claudio Festuccia. 2016. “Dual PI3K/MTOR Inhibitor, XL765 (SAR245409), Shows Superior Effects to Sole PI3K [XL147 (SAR245408)] or MTOR [Rapamycin] Inhibition in Prostate Cancer Cell Models.” Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine 37 (1): 341–51. doi:10.1007/s13277-015-3725-3.